Survival of Licenses. The licenses granted to Agile under Section 5.2(b) shall survive expiration or termination of this Agreement on a perpetual basis; provided, however, that the license granted to Agile under Section 5.2(b) shall remain subject to Agile’s continuing payment of all applicable royalties and its ongoing compliance with the other conditions, restrictions and limitations of such license. Agile acknowledges that the license granted under Section 5.2(b) is subject to termination, independent of the rest of this Agreement, in the event that Agile violates any of those conditions, restrictions or limitations (including but not limited to Agile’s royalty obligations, as applicable). Notwithstanding anything to the contrary set forth in this Agreement, Agile may terminate the license granted to Agile under Section 5.2(b) at any time upon written notice to Corium.
Survival of Licenses. The licenses granted to GSK under this Agreement (including under Section 2) and any rights associated with such licenses shall survive the termination of this Agreement.
Survival of Licenses. All licenses granted to the Company (i) are transferrable and assignable together with an assignment of this Agreement in accordance with Section 16.5; and (ii) shall permanently vest and remain in force should Affimed enter into voluntary or involuntary bankruptcy, liquidation, or similar proceedings.
Survival of Licenses. Notwithstanding anything herein, on a Licensed Product-by-Licensed Product and country-by-country basis, upon the expiration (but not the earlier termination) of all royalty payment obligations for a Licensed Product in a country, the licenses granted to SANOFI-AVENTIS in Section 7.1 shall be deemed to be perpetual and fully paid-up with respect to such Licensed Product in such country.
Survival of Licenses. All rights and licenses granted to Guardian under the Agreements (other than with respect to trademarks) with respect to either Project-Related Technology that is owned or co-owned by Intermolecular under the Wet Coating Master Agreement or the Program Technology under the Sputtered Coating Master Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101 of the Bankruptcy Code. The parties agree that Guardian, as a licensee of such rights under the Agreements, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code. The parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against Intermolecular under the Bankruptcy Code, Guardian shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and same, if not already in its possession, shall be promptly delivered to Guardian upon Guardian’s written request (i) upon any such commencement of a bankruptcy proceeding, unless Intermolecular elects to continue to perform all of its obligations under the Agreements; or (ii) if not delivered under (i) above, upon the rejection of either Agreement by or on behalf of Intermolecular.
Survival of Licenses. Upon the expiration of the Country Term with respect to each Product in each country, the licenses that Novartis grants or may grant to Idenix pursuant to Sections 6.2(a)(i) and 6.2(b), respectively, shall be deemed to be perpetual, fully paid up, but non-exclusive, with respect to such Product in such country.
Survival of Licenses. In the event that a Party to this IPAL Agreement attempts to assign this IPAL Agreement in a manner not permitted hereunder, the licenses granted to such Party in this IPAL Agreement shall immediately terminate, but the licenses granted by such Party to the other Party hereunder shall not terminate and shall remain in full force and effect.
Survival of Licenses. Upon the expiration of Novartis’ payment obligations under Section 6.2 with respect to each Idenix HCV Product in each country, the licenses granted to Novartis pursuant to Section 4.1.2 shall be perpetual and fully paid-up with respect to such Idenix HCV Product in such country.
Survival of Licenses. Notwithstanding anything herein, on a Licensed Product-by-Licensed Product and country-by-country basis, upon the expiration (but not the earlier termination) of all royalty payment obligations for a Licensed Product in a country, the licenses granted to Ipsen in Section 7.1 shall be deemed to be perpetual and fully paid-up with respect to such Licensed Product in such country. Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.
Survival of Licenses. Upon the expiration of CTI's obligations to pay royalties to Xxxxxx under Section 6.4 with respect to Product in each country, the licenses set forth in Article 2 shall be deemed to be perpetual, irrevocable and fully-paid up with respect to Product in such country.
